NCT06597682View on ClinicalTrials.gov

Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction

NANot yet recruitingINTERVENTIONAL
Enrollment

632

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Post-acute Sequelae of SARS-COV-2 Infection
Interventions
DRUG

Prednisone

Total 4 weeks of treatment

DRUG

Budesonide/Formoterol

Total 8 weeks of treatment

DRUG

Vitamin C combined with Coenzyme Q10 oral treatment

Total 4 weeks of treatment

DRUG

Montelukast tablets oral treatment

Total 8 weeks of treatment

Trial Locations (1)

200040

Huashan Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Huashan Hospital

OTHER

NCT06597682 - Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction | Biotech Hunter | Biotech Hunter